Research by Mercè Boada has shown that TPE with albumin replacement can improve cognitive symptoms and slow cognitive decline in AD patients [856, 859], while IVIG-based treatments yielded mild-to-moderate cognitive improvements up to two years post-treatment [1765–1767]. This evidence concerns the gene ALB and Alzheimer disease.